Jpmorgan Chase & CO Elevation Oncology, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 65,752 shares of ELEV stock, worth $19,725. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,752
Previous 180,375
63.55%
Holding current value
$19,725
Previous $104,000
83.65%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ELEV
# of Institutions
73Shares Held
33.2MCall Options Held
65KPut Options Held
4K-
Frazier Life Sciences Management, L.P. Menlo Park, CA5.99MShares$1.8 Million0.1% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.89MShares$1.77 Million1.24% of portfolio
-
Tang Capital Management LLC San Diego, CA4.76MShares$1.43 Million0.08% of portfolio
-
Aisling Capital Management LP New York, NY2.83MShares$850,4730.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.59MShares$775,5660.0% of portfolio
About Elevation Oncology, Inc.
- Ticker ELEV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,300,900
- Market Cap $6.99M
- Description
- Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...